Adverse drug reactions associated with antipsychotics, antidepressants, and mood stabilizers

Nursing Clinics of North America

Volumn 38, Issue 1, 2003, Pages 161-176

  Antai Otong, Deborah ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZATROPINE MESILATE; CARBAMAZEPINE; DIPHENHYDRAMINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE; TRANQUILIZER;

AKATHISIA; CLINICAL FEATURE; CONFUSION; DIAPHORESIS; DISEASE SEVERITY; DISORIENTATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERTHERMIA; HYPOXIA; INSOMNIA; KIDNEY FAILURE; LEUKOCYTOSIS; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NURSE ATTITUDE; NURSING; PARKINSONISM; POSITIVE SYNDROME; RECEPTOR SOLUBILIZATION; RESPIRATORY DISTRESS; REVIEW; SEDATION; SEXUAL DYSFUNCTION; STANDING; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 0038446326     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-6465(02)00069-5     Document Type: Review

References (33)

1. Lazarou J., Pomeranz B.H., Covey P.N. Incidence of adverse drug reactions in hospitalized patients. JAMA. 279:1998;1200-1205
2. Bates D.W. Drugs and adverse drug reactions: how worried should we be? letter JAMA. 279:1998;1216-1217
3. Tandon R. Antipsychotic agents. Klein D.F., Rowland L.P. Current psychotherapeutic drugs. 1998;120-124 Brunner/Mazel Publishers, New York
4. Bilder R.M. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry. 42:1997;255-264
5. Jibson M.D., Tandon R. The negative symptoms of schizophrenia. Directions in Psychiatry. 15:1995;1-7
6. Brendel D.H., Bodkin J.A., Yang J.M. Massive sertraline overdose. Ann Emerg Med. 36:2000;524-526
7. Cardoso F., Jankovic J. Dystonia and dyskinesia. Psychiatr Clin N Am. 20:1997;821-838
8. Glazer W.M., Morgenstern H., Doucette J.T. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 54:1993;133-139
9. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 50:1993;723-733
10. Pelonero A.L., Levenson J.K., Pandurangi A.K. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 49:1998;1163-1172
11. Bezchlibnyk-Butler K.Z., Jeffries J.J. Clinical handbook of psychotropic drugs. 10th edition :2000;Hogrefe & Huber Publishers, Seattle (WA)
12. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476
13. Westerink B.H.C., Kawahara Y., De Boer P., et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol. 412:2001;127-138
14. Glassman A.H., Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 158:2001;1774-1782
15. 1A receptor activation: a possible mechanism of atypical-induced cortical dopamine release. J Neurochem. 76:2001;1521-1531
16. Gorman J. Mirtazapine: clinical overview. J Clin Psychiatry. 60:1999;9-12
17. McCarty C.A., Wood C.A., Fu C.L., et al. Schizophrenia, psychotropic medication, and cataract. Ophthalmology. 106:1999;683-687
18. Smith D., Pantelis C., McGrath J., et al. Ocular abnormalities in chronic schizophrenia: clinical implications. Aust N Z J Psychiatry. 31:1997;252-256
19. Buckley N.A., Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 23:2000;215-228
20. Welch R., Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 25:2000;154-160
21. Murray C.J., Lopez A.D. The global burden of disease. 1996;World Health Organization, Geneva
22. American Psychiatric Association Work Group. Practice guideline for the treatment of patients with major depressive disorder (revision). 2000;American Psychiatric Association, Washington, DC
23. Reimherr F.W., Amsterdam J.D., Quitkin F.M., et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 155:1998;1247-1253
24. Martin R., Kuzniecky R., Ho S., et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 52:1999;321-327
25. Leo R.J. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 57:1996;449-454
26. Coupland N.J., Bell C.J., Potokar J.P. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 16:1996;356-362
27. Sporer K.A. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf. 13:1995;94-104
28. Nijhawan P.K., Katz G., Winter S. Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission. Crit Care Med. 24:1996;1086-1089
29. Gitlin M.J., Suri R. Management of side effects of SSRIs and newer antidepressants. Balon R. Practical management of side effects of psychotropic drugs. 1999;85-118 Marcel Dekker, New York
30. Robinson D.S., Roberts D.L., Smith J.M., et al. The safety profile of nefazodone. J Clin Psychiatry. 57:(Suppl 2):1996;31-38
31. Rosenstein DL, Nelson SC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 54:289-9.
32. Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet. 353:1999;2190-2194
33. Webb A.L., Solomon D.A., Ryan C.E. Lithium levels and toxicity among hospitalized patients. Psychiatr Serv. 52:2001;229-231